Knight Cancer signal achievements of 2022
People at the Knight Cancer Institute accomplished a lot in 2022. Through innovative, collaborative research and education, the institute delivers cancer prevention, detection, and care — one...
Tag: regorafenib
The cancer kept coming back
His life was blasted apart by a rare but vicious type of cancer. Could an experimental treatment help? When Derek Fadness woke up, the room was dark and his face was swaddled in bandages. He could...
Targeting osteosarcoma, a cancer more common in young people
Knight Cancer researchers describe positive results with the drug regorafenib. Osteosarcoma is a bone cancer that disproportionately affects teenagers, and despite substantial efforts, outcomes for...
Positive results with a targeted therapy for osteosarcoma, a cancer more common in young people
Osteosarcoma is a bone cancer that disproportionately affects teenagers, and outcomes for patients have changed little in decades. Now researchers, including two OHSU Knight Cancer Institute...